person · Reporting owner

Bristol James Arthur

Disclosed activity across 3 companies

Tapewire entity: 18227
SEC CIK: 0001715153

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Erasca, Inc.ERAS · Entity 3796	Director	June 26, 2026	June 29, 2026
Ernexa Therapeutics Inc.ERNA · Entity 8278	Director	August 31, 2026	September 02, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Erasca, Inc.

Report date June 26, 2026 · Filed June 29, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.01 · Expires 2036-06-26	Direct	29,888	Reported balance After 2026-06-26 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-26 · Grant · Acquired 29,888 · Balance 29,888 F1: 100% of the options to purchase shares vest on June 26, 2027, subject to the Reporting Person's continuous service to the Issuer on such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: 100% of the options to purchase shares vest on June 26, 2027, subject to the Reporting Person's continuous service to the Issuer on such vesting date.

Ernexa Therapeutics Inc.

Report date August 31, 2026 · Filed September 02, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.57 · Expires 2036-08-31	Direct	8,320	Reported balance After 2026-08-31 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-08-31 · Grant · Acquired 8,320 · Balance 8,320 F1: Subject to continued service, one-third of the shares underlying the stock option will vest on the first anniversary of the grant date, and the remaining shares underlying the stock option will vest in 24 substantially equal monthly installments thereafter.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.57 · Expires 2036-08-31	Direct	5,083	Reported balance After 2026-08-31 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-08-31 · Grant · Acquired 5,083 · Balance 5,083 F2: Represents options to purchase shares of the registrant's common stock in lieu of prorated director's cash compensation for 2026 pursuant to the Director's Compensation Plan effective August 15, 2026, granted under the Issuer's 2026 Omnibus Equity Incentive Plan. Subject to continued service, 100% of the stock options will vest on December 31, 2026.

Filing footnotes · ownership attribution and instrument terms

F1: Subject to continued service, one-third of the shares underlying the stock option will vest on the first anniversary of the grant date, and the remaining shares underlying the stock option will vest in 24 substantially equal monthly installments thereafter.

F2: Represents options to purchase shares of the registrant's common stock in lieu of prorated director's cash compensation for 2026 pursuant to the Director's Compensation Plan effective August 15, 2026, granted under the Issuer's 2026 Omnibus Equity Incentive Plan. Subject to continued service, 100% of the stock options will vest on December 31, 2026.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Deciphera Pharmaceuticals, Inc.

Report date June 11, 2024 · Filed June 11, 2024

Section 16 reporting ended · disclosed 2024-06-11. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.95	IndirectBy Bristol Survivor's Trust	Reported balance After 2024-06-11 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2024-06-11 · Disposition to issuer · Disposed 22,150 · Balance 0 F1: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.13	IndirectBy Bristol Survivor's Trust	Reported balance After 2024-06-11 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2024-06-11 · Disposition to issuer · Disposed 67,494 · Balance 0 F1: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.05	IndirectBy Bristol Survivor's Trust	Reported balance After 2024-06-11 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2024-06-11 · Disposition to issuer · Disposed 12,000 · Balance 0 F1: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.27	IndirectBy Bristol Survivor's Trust	Reported balance After 2024-06-11 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2024-06-11 · Disposition to issuer · Disposed 9,570 · Balance 0 F1: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.98	IndirectBy Bristol Survivor's Trust	Reported balance After 2024-06-11 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2024-06-11 · Disposition to issuer · Disposed 18,500 · Balance 0 F1: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.91	IndirectBy Bristol Survivor's Trust	Reported balance After 2024-06-11 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2024-06-11 · Disposition to issuer · Disposed 30,000 · Balance 0 F1: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent.

F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
July 09, 2020 Filed Jul 13, 2020 16:11 UTC	Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033	Exercise / conversionCommon Stock	7,217	$1.89	$13,640.13	Disclosure SEC source: 0001209191-20-042243 · doc4.xml · nonDerivative · entry 2 Bristol James Arthur · CIK 0001715153 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,541 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
July 09, 2020 Filed Jul 13, 2020 16:11 UTC	Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033	Exercise / conversionCommon Stock	16,324	$1.89	$30,852.36	Disclosure SEC source: 0001209191-20-042243 · doc4.xml · nonDerivative · entry 1 Bristol James Arthur · CIK 0001715153 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,324 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 10, 2020 Filed Jun 12, 2020 16:00 UTC	Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033	GrantStock Option (Right to Buy) · Derivative	12,000	$0.00 Strike: $56.46	$0.00	Disclosure SEC source: 0001209191-20-036239 · doc4.xml · derivative · entry 1 Bristol James Arthur · CIK 0001715153 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2030-06-10 F1 · derivative.exercise_date: This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. The option shall vest in full on June 10, 2021, subject to continued service through such date. Read SEC document
April 09, 2020 Filed Apr 13, 2020 19:47 UTC	Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033	Exercise / conversionStock Option (Right to Buy) · Derivative	23,542	$0.00 Strike: $1.89	$0.00	Disclosure SEC source: 0001209191-20-024252 · doc4.xml · derivative · entry 6 Bristol James Arthur · CIK 0001715153 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,324 Underlying: Common Stock · 23,542 shares Expires 2025-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option was 100% exercisable on the date of grant, December 18, 2015. Read SEC document
April 09, 2020 Filed Apr 13, 2020 19:47 UTC	Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033	SaleCommon Stock	536	$45.88	$24,593.56	Disclosure SEC source: 0001209191-20-024252 · doc4.xml · nonDerivative · entry 5 Bristol James Arthur · CIK 0001715153 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.46 to $45.99, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document
April 09, 2020 Filed Apr 13, 2020 19:47 UTC	Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033	SaleCommon Stock	11,012	$44.18	$486,482.63	Disclosure SEC source: 0001209191-20-024252 · doc4.xml · nonDerivative · entry 4 Bristol James Arthur · CIK 0001715153 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 536 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.45 to $45.34, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document
April 09, 2020 Filed Apr 13, 2020 19:47 UTC	Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033	SaleCommon Stock	5,621	$43.93	$246,916.48	Disclosure SEC source: 0001209191-20-024252 · doc4.xml · nonDerivative · entry 3 Bristol James Arthur · CIK 0001715153 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,548 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.43 to $44.39, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document
April 09, 2020 Filed Apr 13, 2020 19:47 UTC	Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033	SaleCommon Stock	6,373	$42.97	$273,847.17	Disclosure SEC source: 0001209191-20-024252 · doc4.xml · nonDerivative · entry 2 Bristol James Arthur · CIK 0001715153 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,169 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.43 to $43.41, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document
April 09, 2020 Filed Apr 13, 2020 19:47 UTC	Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033	Exercise / conversionCommon Stock	23,542	$1.89	$44,494.38	Disclosure SEC source: 0001209191-20-024252 · doc4.xml · nonDerivative · entry 1 Bristol James Arthur · CIK 0001715153 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,542 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 03, 2020 Filed Jan 6, 2020 16:15 UTC	Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033	Exercise / conversionStock Option (Right to Buy) · Derivative	7,989	$0.00 Strike: $1.89	$0.00	Disclosure SEC source: 0001209191-20-001755 · doc4.xml · derivative · entry 12 Bristol James Arthur · CIK 0001715153 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,866 Underlying: Common Stock · 7,989 shares Expires 2025-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option was 100% exercisable on the date of grant, December 18, 2015. Read SEC document
January 03, 2020 Filed Jan 6, 2020 16:15 UTC	Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033	SaleCommon Stock	200	$58.72	$11,744.00	Disclosure SEC source: 0001209191-20-001755 · doc4.xml · nonDerivative · entry 10 Bristol James Arthur · CIK 0001715153 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.70 to $58.75, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document
January 03, 2020 Filed Jan 6, 2020 16:15 UTC	Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033	SaleCommon Stock	1,810	$58.17	$105,281.73	Disclosure SEC source: 0001209191-20-001755 · doc4.xml · nonDerivative · entry 9 Bristol James Arthur · CIK 0001715153 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.66 to $58.65, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document
January 03, 2020 Filed Jan 6, 2020 16:15 UTC	Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033	SaleCommon Stock	5,250	$57.21	$300,372.45	Disclosure SEC source: 0001209191-20-001755 · doc4.xml · nonDerivative · entry 8 Bristol James Arthur · CIK 0001715153 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,010 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.63 to $57.57, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document
January 03, 2020 Filed Jan 6, 2020 16:15 UTC	Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033	SaleCommon Stock	729	$55.96	$40,797.32	Disclosure SEC source: 0001209191-20-001755 · doc4.xml · nonDerivative · entry 7 Bristol James Arthur · CIK 0001715153 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,260 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.55 to $56.38, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document
January 03, 2020 Filed Jan 6, 2020 16:15 UTC	Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033	Exercise / conversionCommon Stock	7,989	$1.89	$15,099.21	Disclosure SEC source: 0001209191-20-001755 · doc4.xml · nonDerivative · entry 6 Bristol James Arthur · CIK 0001715153 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,989 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 02, 2020 Filed Jan 6, 2020 16:15 UTC	Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033	Exercise / conversionStock Option (Right to Buy) · Derivative	15,553	$0.00 Strike: $1.89	$0.00	Disclosure SEC source: 0001209191-20-001755 · doc4.xml · derivative · entry 11 Bristol James Arthur · CIK 0001715153 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,855 Underlying: Common Stock · 15,553 shares Expires 2025-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option was 100% exercisable on the date of grant, December 18, 2015. Read SEC document
January 02, 2020 Filed Jan 6, 2020 16:15 UTC	Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033	SaleCommon Stock	300	$61.87	$18,561.00	Disclosure SEC source: 0001209191-20-001755 · doc4.xml · nonDerivative · entry 5 Bristol James Arthur · CIK 0001715153 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.68 to $62.25, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document
January 02, 2020 Filed Jan 6, 2020 16:15 UTC	Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033	SaleCommon Stock	365	$59.38	$21,675.23	Disclosure SEC source: 0001209191-20-001755 · doc4.xml · nonDerivative · entry 4 Bristol James Arthur · CIK 0001715153 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.17 to $59.56, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document
January 02, 2020 Filed Jan 6, 2020 16:15 UTC	Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033	SaleCommon Stock	5,347	$58.08	$310,566.59	Disclosure SEC source: 0001209191-20-001755 · doc4.xml · nonDerivative · entry 3 Bristol James Arthur · CIK 0001715153 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 665 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.87 to $58.73, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document
January 02, 2020 Filed Jan 6, 2020 16:15 UTC	Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033	SaleCommon Stock	9,541	$57.51	$548,664.75	Disclosure SEC source: 0001209191-20-001755 · doc4.xml · nonDerivative · entry 2 Bristol James Arthur · CIK 0001715153 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,012 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.87 to $57.86, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document
January 02, 2020 Filed Jan 6, 2020 16:15 UTC	Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033	Exercise / conversionCommon Stock	15,553	$1.89	$29,395.17	Disclosure SEC source: 0001209191-20-001755 · doc4.xml · nonDerivative · entry 1 Bristol James Arthur · CIK 0001715153 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,553 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 01, 2019 Filed Nov 5, 2019 16:16 UTC	Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033	Exercise / conversionStock Option (Right to Buy) · Derivative	25,000	$0.00 Strike: $1.89	$0.00	Disclosure SEC source: 0001209191-19-055179 · doc4.xml · derivative · entry 3 Bristol James Arthur · CIK 0001715153 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,408 Underlying: Common Stock · 25,000 shares Expires 2025-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option was 100% exercisable on the date of grant, December 18, 2015. Read SEC document
November 01, 2019 Filed Nov 5, 2019 16:16 UTC	Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033	SaleCommon Stock	25,000	$45.07	$1,126,822.50	Disclosure SEC source: 0001209191-19-055179 · doc4.xml · nonDerivative · entry 2 Bristol James Arthur · CIK 0001715153 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.4650, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document
November 01, 2019 Filed Nov 5, 2019 16:16 UTC	Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033	Exercise / conversionCommon Stock	25,000	$1.89	$47,250.00	Disclosure SEC source: 0001209191-19-055179 · doc4.xml · nonDerivative · entry 1 Bristol James Arthur · CIK 0001715153 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
August 13, 2019 Filed Aug 13, 2019 19:51 UTC	Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033	Exercise / conversionStock Option (Right to Buy) · Derivative	25,000	$0.00 Strike: $1.89	$0.00	Disclosure SEC source: 0001209191-19-045816 · doc4.xml · derivative · entry 6 Bristol James Arthur · CIK 0001715153 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,408 Underlying: Common Stock · 25,000 shares Expires 2025-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option was 100% exercisable on the date of grant, December 18, 2015. Read SEC document
August 13, 2019 Filed Aug 13, 2019 19:51 UTC	Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033	SaleCommon Stock	100	$42.90	$4,290.00	Disclosure SEC source: 0001209191-19-045816 · doc4.xml · nonDerivative · entry 5 Bristol James Arthur · CIK 0001715153 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document
August 13, 2019 Filed Aug 13, 2019 19:51 UTC	Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033	SaleCommon Stock	700	$42.05	$29,435.07	Disclosure SEC source: 0001209191-19-045816 · doc4.xml · nonDerivative · entry 4 Bristol James Arthur · CIK 0001715153 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.67 to $42.53, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document
August 13, 2019 Filed Aug 13, 2019 19:51 UTC	Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033	SaleCommon Stock	12,687	$40.50	$513,842.53	Disclosure SEC source: 0001209191-19-045816 · doc4.xml · nonDerivative · entry 3 Bristol James Arthur · CIK 0001715153 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 800 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.13 to $41.01, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document
August 13, 2019 Filed Aug 13, 2019 19:51 UTC	Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033	SaleCommon Stock	11,513	$39.24	$451,797.75	Disclosure SEC source: 0001209191-19-045816 · doc4.xml · nonDerivative · entry 2 Bristol James Arthur · CIK 0001715153 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,487 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.10 to $40.00, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document
August 13, 2019 Filed Aug 13, 2019 19:51 UTC	Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033	Exercise / conversionCommon Stock	25,000	$1.89	$47,250.00	Disclosure SEC source: 0001209191-19-045816 · doc4.xml · nonDerivative · entry 1 Bristol James Arthur · CIK 0001715153 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 11, 2019 Filed Jun 13, 2019 16:11 UTC	Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033	GrantStock Option (Right to Buy) · Derivative	12,000	$0.00 Strike: $21.05	$0.00	Disclosure SEC source: 0001209191-19-036742 · doc4.xml · derivative · entry 1 Bristol James Arthur · CIK 0001715153 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2029-06-11 F1 · derivative.exercise_date: This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. The option shall vest in full on June 11, 2020, subject to continued service through such date. Read SEC document
February 15, 2019 Filed Feb 19, 2019 19:25 UTC	Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033	Exercise / conversionStock Option (Right to Buy) · Derivative	17,782	$0.00 Strike: $1.89	$0.00	Disclosure SEC source: 0001209191-19-011360 · doc4.xml · derivative · entry 6 Bristol James Arthur · CIK 0001715153 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,408 Underlying: Common Stock · 17,782 shares Expires 2025-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option was 100% exercisable on the date of grant, December 18, 2015. Read SEC document
February 15, 2019 Filed Feb 19, 2019 19:25 UTC	Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033	SaleCommon Stock	17,782	$28.04	$498,603.72	Disclosure SEC source: 0001209191-19-011360 · doc4.xml · nonDerivative · entry 4 Bristol James Arthur · CIK 0001715153 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.00 to $28.06, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document
February 15, 2019 Filed Feb 19, 2019 19:25 UTC	Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033	Exercise / conversionCommon Stock	17,782	$1.89	$33,607.98	Disclosure SEC source: 0001209191-19-011360 · doc4.xml · nonDerivative · entry 3 Bristol James Arthur · CIK 0001715153 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,782 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 14, 2019 Filed Feb 19, 2019 19:25 UTC	Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033	Exercise / conversionStock Option (Right to Buy) · Derivative	1,101	$0.00 Strike: $1.89	$0.00	Disclosure SEC source: 0001209191-19-011360 · doc4.xml · derivative · entry 5 Bristol James Arthur · CIK 0001715153 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,190 Underlying: Common Stock · 1,101 shares Expires 2025-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option was 100% exercisable on the date of grant, December 18, 2015. Read SEC document
February 14, 2019 Filed Feb 19, 2019 19:25 UTC	Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033	SaleCommon Stock	1,101	$28.01	$30,841.87	Disclosure SEC source: 0001209191-19-011360 · doc4.xml · nonDerivative · entry 2 Bristol James Arthur · CIK 0001715153 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.00 to $28.04, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document
February 14, 2019 Filed Feb 19, 2019 19:25 UTC	Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033	Exercise / conversionCommon Stock	1,101	$1.89	$2,080.89	Disclosure SEC source: 0001209191-19-011360 · doc4.xml · nonDerivative · entry 1 Bristol James Arthur · CIK 0001715153 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,101 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 13, 2019 Filed Feb 14, 2019 16:22 UTC	Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033	Exercise / conversionStock Option (Right to Buy) · Derivative	2,922	$0.00 Strike: $1.89	$0.00	Disclosure SEC source: 0001209191-19-010144 · doc4.xml · derivative · entry 6 Bristol James Arthur · CIK 0001715153 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,291 Underlying: Common Stock · 2,922 shares Expires 2025-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option was 100% exercisable on the date of grant, December 18, 2015. Read SEC document
February 13, 2019 Filed Feb 14, 2019 16:22 UTC	Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033	SaleCommon Stock	2,922	$28.01	$81,835.58	Disclosure SEC source: 0001209191-19-010144 · doc4.xml · nonDerivative · entry 4 Bristol James Arthur · CIK 0001715153 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.00 to $28.07, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document
February 13, 2019 Filed Feb 14, 2019 16:22 UTC	Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033	Exercise / conversionCommon Stock	2,922	$1.89	$5,522.58	Disclosure SEC source: 0001209191-19-010144 · doc4.xml · nonDerivative · entry 3 Bristol James Arthur · CIK 0001715153 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,922 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 12, 2019 Filed Feb 14, 2019 16:22 UTC	Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033	Exercise / conversionStock Option (Right to Buy) · Derivative	600	$0.00 Strike: $1.89	$0.00	Disclosure SEC source: 0001209191-19-010144 · doc4.xml · derivative · entry 5 Bristol James Arthur · CIK 0001715153 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,213 Underlying: Common Stock · 600 shares Expires 2025-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option was 100% exercisable on the date of grant, December 18, 2015. Read SEC document
February 12, 2019 Filed Feb 14, 2019 16:22 UTC	Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033	SaleCommon Stock	600	$28.00	$16,801.02	Disclosure SEC source: 0001209191-19-010144 · doc4.xml · nonDerivative · entry 2 Bristol James Arthur · CIK 0001715153 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.00 to $28.01, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document
February 12, 2019 Filed Feb 14, 2019 16:22 UTC	Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033	Exercise / conversionCommon Stock	600	$1.89	$1,134.00	Disclosure SEC source: 0001209191-19-010144 · doc4.xml · nonDerivative · entry 1 Bristol James Arthur · CIK 0001715153 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 05, 2019 Filed Feb 7, 2019 16:09 UTC	Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033	Exercise / conversionStock Option (Right to Buy) · Derivative	2,595	$0.00 Strike: $1.89	$0.00	Disclosure SEC source: 0001209191-19-008046 · doc4.xml · derivative · entry 3 Bristol James Arthur · CIK 0001715153 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,813 Underlying: Common Stock · 2,595 shares Expires 2025-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option was 100% exercisable on the date of grant, December 18, 2015. Read SEC document
February 05, 2019 Filed Feb 7, 2019 16:09 UTC	Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033	SaleCommon Stock	2,595	$28.02	$72,704.12	Disclosure SEC source: 0001209191-19-008046 · doc4.xml · nonDerivative · entry 2 Bristol James Arthur · CIK 0001715153 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.00 to $28.08, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document
February 05, 2019 Filed Feb 7, 2019 16:09 UTC	Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033	Exercise / conversionCommon Stock	2,595	$1.89	$4,904.55	Disclosure SEC source: 0001209191-19-008046 · doc4.xml · nonDerivative · entry 1 Bristol James Arthur · CIK 0001715153 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,595 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 17, 2018 Filed May 21, 2018 16:23 UTC	Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033	GrantStock Option (Right to Buy) · Derivative	12,000	$0.00 Strike: $25.73	$0.00	Disclosure SEC source: 0000899243-18-013548 · doc4.xml · derivative · entry 1 Bristol James Arthur · CIK 0001715153 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2028-05-16 F1 · derivative.exercise_date: This stock option award was issued pursuant to Issuer's 2017 Stock Option and Incentive Plan and will vest in full on May 17, 2019, subject to the Reporting Person's continuous service with the Issuer. Read SEC document
October 02, 2017 Filed Oct 2, 2017 16:41 UTC	Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033	Exercise / conversionStock Option (Right to Buy) · Derivative	67,494	Not disclosed Strike: $6.13	Not disclosed	Disclosure SEC source: 0000899243-17-023139 · doc4.xml · derivative · entry 8 Bristol James Arthur · CIK 0001715153 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,494 Underlying: Common Stock · 67,494 shares Expires 2027-06-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: Represents the total number of options to purchase common stock of the Issuer received upon the exchange of options to purchase common stock of Deciphera Pharmaceuticals, Inc. for options to purchase common stock of the Issuer pursuant to the Merger Agreement. F1 · price: Immediately prior to the closing of the Issuer's initial public offering, these options to purchase common stock of Deciphera Pharmaceuticals, LLC were exchanged for options to purchase common stock of the Issuer on a 1 for 5.65 basis pursuant to that certain Reorganization Agreement and Plan of Merger by and among the Issuer, Deciphera Pharmaceuticals, LLC and the other parties named therein, dated September 26, 2017 (the "Merger Agreement"). These transactions were exempt from Section 16(b) in reliance upon Rule 16b-3 and Rule 16b-6(b). F6 · derivative.exercise_date: This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option vests in 48 equal monthly installments at the end of each month following the vesting commencement date of May 26, 2017, subject to continued service through Read SEC document
October 02, 2017 Filed Oct 2, 2017 16:41 UTC	Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033	Exercise / conversionStock Option (Right to Buy) · Derivative	11,946	Not disclosed Strike: $6.13	Not disclosed	Disclosure SEC source: 0000899243-17-023139 · doc4.xml · derivative · entry 7 Bristol James Arthur · CIK 0001715153 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 67,494 shares Expires 2027-06-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Immediately prior to the closing of the Issuer's initial public offering, these options to purchase common stock of Deciphera Pharmaceuticals, LLC were exchanged for options to purchase common stock of the Issuer on a 1 for 5.65 basis pursuant to that certain Reorganization Agreement and Plan of Merger by and among the Issuer, Deciphera Pharmaceuticals, LLC and the other parties named therein, dated September 26, 2017 (the "Merger Agreement"). These transactions were exempt from Section 16(b) in reliance upon Rule 16b-3 and Rule 16b-6(b). F1 · price: Immediately prior to the closing of the Issuer's initial public offering, these options to purchase common stock of Deciphera Pharmaceuticals, LLC were exchanged for options to purchase common stock of the Issuer on a 1 for 5.65 basis pursuant to that certain Reorganization Agreement and Plan of Merger by and among the Issuer, Deciphera Pharmaceuticals, LLC and the other parties named therein, dated September 26, 2017 (the "Merger Agreement"). These transactions were exempt from Section 16(b) in reliance upon Rule 16b-3 and Rule 16b-6(b). F6 · derivative.exercise_date: This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option vests in 48 equal monthly installments at the end of each month following the vesting commencement date of May 26, 2017, subject to continued service through Read SEC document
October 02, 2017 Filed Oct 2, 2017 16:41 UTC	Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033	Exercise / conversionStock Option (Right to Buy) · Derivative	50,850	Not disclosed Strike: $3.95	Not disclosed	Disclosure SEC source: 0000899243-17-023139 · doc4.xml · derivative · entry 6 Bristol James Arthur · CIK 0001715153 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,580 Underlying: Common Stock · 50,580 shares Expires 2026-09-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: Represents the total number of options to purchase common stock of the Issuer received upon the exchange of options to purchase common stock of Deciphera Pharmaceuticals, Inc. for options to purchase common stock of the Issuer pursuant to the Merger Agreement. F1 · price: Immediately prior to the closing of the Issuer's initial public offering, these options to purchase common stock of Deciphera Pharmaceuticals, LLC were exchanged for options to purchase common stock of the Issuer on a 1 for 5.65 basis pursuant to that certain Reorganization Agreement and Plan of Merger by and among the Issuer, Deciphera Pharmaceuticals, LLC and the other parties named therein, dated September 26, 2017 (the "Merger Agreement"). These transactions were exempt from Section 16(b) in reliance upon Rule 16b-3 and Rule 16b-6(b). F5 · derivative.exercise_date: This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option vests in 48 equal monthly installments at the end of each month following the vesting commencement date of July 1, 2016, subject to continued service through such dates. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.